Overall brain controlNo. of participants: 203(2 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Neurological function improvement: lower‐dose WBRT vs control dose WBRT (3000 cGy/10 fractions)No. of participants: 1612(5 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules probably leads to higher neurological function improvement: lower‐dose WBRT vs control dose… compared with WBRT control: neurological function improvement (moderate certainty).
1 finding from 1 review
OR 1.74 [1.06, 2.84]
Studies not reported
Moderate
Neurological function improvement: higher‐dose WBRT vs control dose WBRT (3000 cGy/10 fractions)No. of participants: 1480(4 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules showed no clear difference in neurological function improvement: higher‐dose WBRT vs control dose… compared with WBRT control: neurological function improvement (moderate certainty).
1 finding from 1 review
OR 1.14 [0.92, 1.42]
Studies not reported
Moderate
Overall survivalNo. of participants: 2631(8 RCTs) · patients with newly diagnosed multiple brain metastases
WBRT with radiosensitisers (radiosen) showed no clear difference in overall survivalNo. of participants: 2631(8 RCTs) compared with WBRT alone (moderate certainty).
1 finding from 1 review
HR 1.05 [0.99, 1.12]
Studies not reported
Moderate
Intervention not reported
Annualised relapse rate (ARR) (number of relapses per patient per year) · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
Expanded Disability Status Scale (EDSS) score · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
MRI gadolinium‐enhancing T1 lesions · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
Serious adverse events · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
Minor adverse events · [People] with [Multiple Sclerosis]
1 finding from 1 review
Outcomes (see also Table 3) · people with multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Knowledge · people with multiple sclerosis
1 finding from 1 review
Decision making · people with multiple sclerosis
1 finding from 1 review
Quality of life · people with multiple sclerosis
1 finding from 1 review
Adverse events · people with multiple sclerosis
1 finding from 1 review
Attachment change · Adult patients with multiple recession-type defects (Miller Class I/II, at least 3 mm)
PRF + CAF led to lower clinical attachment level change compared with SCTG + CAF; GRADE not reported.
1 finding from 1 review
MD -0.37 [-0.69, -0.06]
2 studies
GRADE not reported
Change in gingival recession (REC) · Adult patients with multiple recession-type defects (Miller Class I/II, at least 3 mm)
PRF + CAF showed no clear difference in gingival recession depth change compared with SCTG + CAF; GRADE not reported.
1 finding from 1 review
MD -0.01 [-0.89, 0.86]
2 studies
GRADE not reported
Intervention not reported
Overall survival## · patients with multiple myeloma
The intervention showed no clear difference in overall survival## (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival### · patients with multiple myeloma
The intervention showed no clear difference in progression‐free survival### (low certainty).
1 finding from 1 review
Intervention not reported
Vertebral fractures · patients with multiple myeloma
The intervention probably leads to lower vertebral fractures (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐vertebral fractures · patients with multiple myeloma
The intervention showed no clear difference in non‐vertebral fractures (moderate certainty).
1 finding from 1 review